

Article

Prognostic Role of CSF β -amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis

Tiziana Colletti ¹, Luisa Agnello ², Rossella Spataro ³, Lavinia Guccione ¹, Antonietta Notaro ¹, Bruna Lo Sasso ², Valeria Blandino ⁴, Fabiola Graziano ⁴, Caterina Maria Gambino ², Rosaria Vincenza Giglio ², Giulia Bivona ², Vincenzo La Bella ¹, Marcello Ciaccio ^{2,†} and Tommaso Piccoli ^{4,*,†}

¹ ALS Clinical Research Center and Laboratory of Neurochemistry, Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy; tizianacolletti@gmail.com (T.C.); lavyguccione@hotmail.it (L.G.); antonietta.notaro@libero.it (A.N.); vincenzo.labela@unipa.it (V.L.B.)

² Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90127 Palermo, Italy; luisa.agnello@unipa.it (L.A.); bruna.losasso@unipa.it (B.L.S.); cmgambino@libero.it (C.M.G.); rosaria.vincenza.giglio@alice.it (R.V.G.); giulia.bivona@unipa.it (G.B.); marcello.ciaccio@unipa.it (M.C.)

³ IRCSS Bonino Pulejo, Presidio Pisani, 90129, Palermo, Italy; rossellaspataro@libero.it

⁴ Unit of Neurology, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, 90129, Palermo, Italy; valeriab@libero.it (V.B.); fabiolagr93@gmail.com (F.G.)

* Correspondence: tommaso.piccoli@unipa.it; Tel.: +39-091-6555-159

† These authors shared the senior authorship and contributed equally to this paper.



Citation: Colletti, T.; Agnello, L.; Spataro, R.; Guccione, L.; Notaro, A.; Lo Sasso, B.; Blandino, V.; Graziano, F.; Gambino, C.M.; Giglio, R.V.; et al. Prognostic Role of CSF β -amyloid 1–42/1–40 Ratio in Patients Affected by Amyotrophic Lateral Sclerosis. *Brain Sci.* **2021**, *11*, 302. <https://doi.org/10.3390/brainsci11030302>

Academic Editor: Melissa Bowerman

Received: 25 January 2021

Accepted: 24 February 2021

Published: 27 February 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The involvement of β -amyloid ($A\beta$) in the pathogenesis of amyotrophic lateral sclerosis (ALS) has been widely discussed and its role in the disease is still a matter of debate. $A\beta$ accumulates in the cortex and the anterior horn neurons of ALS patients and seems to affect their survival. To clarify the role of cerebrospinal fluid (CSF) $A\beta$ 1–42 and $A\beta$ 42/40 ratios as a potential prognostic biomarker for ALS, we performed a retrospective observational study on a cohort of ALS patients who underwent a lumbar puncture at the time of the diagnosis. CSF $A\beta$ 1–40 and $A\beta$ 1–42 ratios were detected by chemiluminescence immunoassay and their values were correlated with clinical features. We found a significant correlation of the $A\beta$ 42/40 ratio with age at onset and Mini Mental State Examination (MMSE) scores. No significant correlation of $A\beta$ 1–42 or $A\beta$ 42/40 ratios to the rate of progression of the disease were found. Furthermore, when we stratified patients according to $A\beta$ 1–42 concentration and the $A\beta$ 42/40 ratio, we found that patients with a lower $A\beta$ 42/40 ratio showed a shorter survival. Our results support the hypothesis that $A\beta$ 1–42 could be involved in some pathogenic mechanism of ALS and we suggest the $A\beta$ 42/40 ratio as a potential prognostic biomarker.

Keywords: ALS; biomarker; beta amyloid

1. Introduction

Amyotrophic lateral sclerosis (ALS) is the most common degenerative motor neuron disease, which results in progressive muscle weakness and causes death in a few years. The pathogenesis of ALS is not fully understood and several pathological processes have been proposed such as abnormal protein aggregation, mitochondrial dysfunction and oxidative stress [1]. To date, the diagnosis of ALS is on clinical features and electrophysiological parameters, indicating the degeneration of both upper and lower motor neurons [2]. Heterogeneity in terms of clinical presentation often makes an early and accurate diagnosis a real challenge for clinicians. For this reason, there has been a growing interest in identifying candidate biomarkers for ALS, which can help make an early diagnosis and predict disease progression. Among these, the role of a neurofilament (NF) phosphorylated

heavy chain (pNF-H) and light chain (NF-L) as potential biomarkers for ALS is defining. NFs have a non-specific and not fully clarified role in the pathogenesis of ALS. The abnormal accumulation of NF aggregates was observed in pericarya and proximal axons of motoneurons both in ALS murine models and patients that seemed to be related to an impairment of intracellular transport [3]. Recently, a few authors have shown that the aggregation of NFs is related to their hyperphosphorylation state [4]. pNF-H and NF-L are increased in the cerebrospinal fluid (CSF) of ALS patients in comparison with control groups [5,6] and the higher levels are associated with a more rapidly evolving disease and shorter survival [7]. The role of other candidate biomarkers (such as Tau proteins) is still under investigation [8–10].

ALS shares common pathways with other neurodegenerative disorders. For example, C9 or f72 repeat expansions and TAR DNA-binding protein (TARDBP) mutations have been described in ALS and frontotemporal lobar degeneration (FTLD), modifying the idea of ALS as a disease confined to the motor system to the extreme phenotypic expression of a clinical/pathological continuum with FTLD [11–13]. Furthermore, the presence of β -amyloid ($A\beta$) deposits at the cortical level, hippocampus and spinal cord motor neurons have been described in ALS patients [14–16], suggesting the possibility of some overlapping features between ALS and Alzheimer's disease (AD).

AD is the most common cause of dementia, characterized by $A\beta$ and Tau deposition, respectively, in senile plaques and neurofibrillary tangles as a result of a complex mechanism known as the amyloid cascade [17]. The amyloid precursor protein (APP) is processed by α -secretase into a soluble form α of the APP (sAPP α) and carboxy-terminal fragment α (CTF α) and by β -secretase sAPP β and CTF β . Subsequently, CTF β is cleaved into $A\beta$ 1–40 or $A\beta$ 1–42 by γ -secretase and the imbalance of this process leads to an over-expression of $A\beta$ 1–42 that precipitates, forming the senile plaques. The consequence is the hyperphosphorylation of the Tau protein and the formation of neurofibrillary tangles [18]. CSF $A\beta$ 1–42 levels combined with total Tau (tTau) and phosphorylated Tau (pTau) are currently used as diagnostic biomarkers for AD with a high sensitivity and specificity [19–22], ameliorating the diagnostic accuracy in the very early stages of the disease.

Due to the pathogenetic similarities among neurodegenerative diseases, possible common pathways between AD and ALS have been investigated. Preclinical studies demonstrated the interaction between superoxide dismutase (SOD) and $A\beta$ and evidence of the amyloid cascade has been reported [23] with an increase of sAPP in the CSF from ALS patients [24] and the post-mortem evidence of the over-expression of APP and $A\beta$ in the hippocampi of ALS patients [17]. On the other hand, it is known that APP regulates glial cell-derived neurotrophic factor (GDNF) expression, having a role on neuromuscular junction formation and probably also in neuromuscular degenerative diseases [23].

Whether or not $A\beta$ has a role in the pathogenesis of ALS is far from being clear but it has been recently proposed that the CSF $A\beta$ 1–42 protein concentration is higher in ALS patients and that it is related to disease severity at the time of diagnosis [25].

Our aim is to evaluate the role of the CSF $A\beta$ 1–42 and $A\beta$ 1–40 concentration and the $A\beta$ 42/40 ratio as a potential predictor factor for progression and overall survival in ALS.

2. Patients and Methods

2.1. Patients

Ninety-three (93) ALS patients (M/F: 1.11) were enrolled from the ALS Clinical and Research Center, Department of Biomedicine, Neuroscience and advanced Diagnostics (Bi.N.D.), University of Palermo, Italy, from January 2001 to October 2020. All ALS patients were diagnosed according to El-Escorial revised criteria [2] combined with the neurophysiological ones [26]. The revised ALS Functional Rating Scale (ALSFRS-R) [27] was used to score the severity of the symptoms of ALS patients; a higher score indicated normality and a lower score defined a locked-in condition. Δ FS ((ALSFRS-R at onset–ALSFRS-R at time of diagnosis)/diagnostic delay) was used to define the disease progression [28]. According to the Δ FS, patients could be classified in three groups: slow progression (Δ FS < 0.5), inter-

mediate progression ($\Delta FS \geq 0.5 < 1$) and rapid progression ($\Delta FS \geq 1$) [28]. We considered co-morbidities for each patient.

All patients underwent a cognitive/behavioral assessment and the administration of neuropsychological tests such as the Frontal Systems Behavioral Scale (FrSBe), Mini Mental State Examination (MMSE) and Edinburgh Cognitive and Behavioral ALS Screen (ECAS) (S-TAB.1). Fewer than 30% showed some degree of behavioral/cognitive impairment according to the Italian Validation of ECAS but none of them were demented. All patients were tested for the most common ALS-related genes and no known mutations associated with ALS were detected.

ALS patients underwent a lumbar puncture (LP) and a CSF analysis as routine procedures of the diagnostic work-up. For the biomarker analysis, ALS patients were subdivided into three subgroups according to the rate of progression based on ΔFS (i.e., slow: ALS-s; intermediate: ALS-i; rapid: ALS-r). All demographic and clinical features of the selected ALS patients are shown in Table 1. None of the patients enrolled assumed any specific drug for ALS treatment at the time of the LP and all of them started riluzole immediately after the diagnosis was made. None of them participated in clinical trials.

Table 1. Demographic and clinical characteristics of the total cohort and amyotrophic lateral sclerosis (ALS) patients stratified based on their rate of progression: slow (ALS-s), intermediate (ALS-i) and rapid (ALS-r). Data are expressed as a median with an interquartile range (IQR).

Variables	ALS tot (n = 93)	ALS-s (n = 19)	ALS-i (n = 31)	ALS-r (n = 35)	p
Age at onset (years)	67 (63–72)	63 (61–67)	67 (64–72)	70 (64–74)	< 0.001 *
M/F	1.11	2.16	1	1.18	0.43 **
Education (years)	5 (5–13)	13 (5–13)	8 (5–8)	5 (5–9)	$\chi^2 = 1.67$ with 2 DF
Type of onset					0.283 *
familiar, %	3.2%	5.2%	3.3%	2.8%	0.90 **
sporadic, %	96.6%	94.8%	96.7%	97.2%	$\chi^2 = 0.22$ with 2 DF
Site of onset					0.09 **
Spinal, %	70.3%	89.5%	63.3%	62.3%	$\chi^2 = 4.80$ with 2 DF
Bulbar, %	29.7%	10.5%	36.7%	37.2%	
Diagnostic delay (months)	12 (9–20)	25 (18–37)	12 (10–24)	7 (4–9.5)	< 0.001 *
Rate of progression (ΔFS) ^A	0.8 (0.5–1.3)	–	–	–	–
FVC ^a (%)	81 (55–93)	84 (59–98)	83 (60–92)	67 (46–93)	0.334 *
BMI ^b (kg/m ²)	24.8 (21.5–27.1)	25 (21–28)	24 (22–27)	25.7 (46–83)	0.355 *
Survival (months)	30 (20–46)	57 (37–67)	35 (27–47)	17 (13–26)	< 0.001 *

^A ΔFS at diagnosis = (ALSFRS-R at onset–ALSFRS-R at diagnosis)/diagnostic delay (months). ^a Forced vital capacity. ^b Body mass index. * Kruskal–Wallis one way analysis of variance on ranks. ** chi-squared test. Bold font indicates a statistical significance ($p < 0.05$).

All patients gave informed written consent. The study was approved by the local Ethics Committee. All of the clinical and biological assessments were carried out in accordance with the World Medical Association Declaration of Helsinki.

2.2. CSF Collection and Analytical Techniques

All CSF samples were collected in the morning hours and then sent to the Central Hospital Laboratory for a routine analysis. For biomarker detection, the CSF samples were centrifuged in case of blood contamination, aliquoted in polypropylene tubes and stored at -80 °C within one hour until further analysis according to international guidelines [29]. The CSF routine chemical parameters are shown in Table 2.

Table 2. Cerebrospinal parameters in ALS patients and in patients with slow (ALS-s), intermediate (ALS-i) and rapid (ALS-r) progression. Data are expressed as a median with an interquartile range (IQR).

Parameters	ALS tot (n = 93)	ALS-s (n = 19)	ALS-i (n = 31)	ALS-r (n = 35)	p *
Proteins (mg/dL)	39 (28–51)	37 (19–52)	39 (32–62)	37 (26–48)	0.524
Glucose (mg/dL)	60 (55–66)	58 (55–63)	56 (51–66)	62 (57–72)	0.103
Cells (lymphocytes)	0.8 (0.6–1.8)	0.8 (0.6–2.3)	1 (0.6–2.9)	0.8 (0.4–1.6)	0.371
Oligoclonal bands (y/n)**	17/76	4/15	4/27	7/28	

* Kruskal–Wallis one way analysis of variance on ranks. ** y = yes, n = no

The CSF A β 1–42 and A β 1–40 were measured by a chemiluminescent immunoassay CLEIA (Lumipulse G b-amyloid 1–40, Lumipulse G b-amyloid 1–42, Fujirebio Inc. Europe, Gent, Belgium) on a fully automatic platform (Lumipulse G1200 analyzer, Fujirebio Inc. Europe, Gent, Belgium). We used as reference cut-off for the A β 1–42 value and the A β 42/40 ratio < 650 pg/ML and < 0.055, respectively, as suggested by the manufacturer.

2.3. Statistical Analyses

All statistical analyses were performed using SIGMAPLOT 12.0 software package (Systat Software Inc., San Jose, CA, USA).

A Shapiro–Wilk test was performed to test the normality of the data. We expressed demographic, clinical and biochemical variables as a median with interquartile ranges (IQR). We performed Kruskal–Wallis one way analysis of variance on ranks to compare non-parametric data, a one way ANOVA to compare parametric data and a chi-squared test to assess differences between the groups. We analyzed non-parametric data with Spearman’s rank correlation coefficient and parametric data with Pearson’s correlation coefficient, considering *p* values < 0.05 as significant.

A survival analysis was performed with the Kaplan–Meier method and survival curves were compared with the log-rank test. Univariate and multivariate Cox regression analyses were performed to predict risk factors for overall survival.

3. Results

A retrospective observational study was performed on 93 ALS patients to analyze the role of A β 1–42, A β 1–40 and the A β 42/40 ratio as candidate biomarkers for ALS. As a few studies have shown that the CSF A β levels are correlated with the rate of progression [21], we stratified ALS patients into three subgroups: ALS-s (*n* = 19; M/F: 2.16), ALS-i (*n* = 31; M/F: 1) and ALS-r (*n* = 35; M/F: 1.18).

In our study, the total cohort of ALS patients had a median age at onset of 67 years. 96.6% of ALS patients were sporadic with a spinal onset in 70.3% of the whole cohort. At the time of diagnosis, ALS patients showed median values of a forced vital capacity (FVC)% of 80.5 (IQR = 54.75–93.25), of a body mass index (BMI) of 24.8 kg/m² (IQR = 21.5–27.12) and of a Δ FS of 0.81 (IQR = 0.5–1.33). The Kruskal–Wallis one way ANOVA with the rate of progression (Δ FS) as a factor showed statistically significant differences in the age of onset (lower in the ALS-s group, *p* < 0.001), diagnostic delay (longer in the ALS-s group, *p* < 0.001) and survival (longer in the ALS-s group, *p* < 0.001); no statistically significant differences were found for the M/F ratio, education, FVC% and BMI (Table 1). The CSF biochemical profile was similar in the three subgroups (Table 2). The neuropsychological assessments with FrSBe, MMSE and ECAS showed no cognitive/behavioral impairments (Table S1).

Analyzing data with the Shapiro–Wilk test, we found that the CSF A β 42/40 values were normally distributed while the A β 1–42 and A β 1–40 ones were not. As shown in Figure 1, the median values of the CSF A β 1–42 concentration and the mean values of the A β 42/40 ratio resulted above the reference cut-off (< 650 pg/mL and < 0.05, respectively).

We found no significant differences among the three ALS subgroups (A β 1–42: $p = 0.685$; A β 1–40: $p = 0.340$; A β 42/40 ratio: $p = 0.426$).




Figure 1. Cerebrospinal fluid (CSF) A β levels in ALS patients and in patients with slow (ALS-s), intermediate (ALS-i) and rapid (ALS-r) progression. (A) A β 1–42; (B) A β 1–40, (C) A β 42/40 ratio. Solid dots in A–C represent known outliers.

Spearman’s correlation analyses for the CSF A β 1–42 and A β 1–40 levels showed no significant correlations (Table 3) while the Pearson’s correlation analysis showed a significant correlation of A β 42/40 ratio values with the age at onset ($r^2 = -0.274$, $p = 0.008$) and MMSE scores ($r^2 = 0.396$, $p = 0.019$) (Table 4).

Table 3. Spearman’s correlation of the CSF A β 1–42 and A β 1–40 with demographic, clinical and neuropsychological features of ALS patients.

	A β 1–42	A β 1–40
Age at onset (years)	$r = -0.041$, $p = 0.695$	$r = 0.312$, $p = 0.208$
Diagnostic delay (months)	$r = -0.140$, $p = 0.189$	$r = -0.163$, $p = 0.126$
Rate of progression (Δ FS)	$r = 0.008$, $p = 0.936$	$r = 0.103$, $p = 0.347$
FVC (%)	$r = 0.141$, $p = 0.237$	$r = 0.116$, $p = 0.330$
FrSBe	$r = 0.125$, $p = 0.370$	$r = 0.185$, $p = 0.196$
MMSE	$r = -0.240$, $p = 0.146$	$r = -0.429$, $p = 0.007$
ECAS	$r = 0.005$, $p = 0.979$	$r = -0.049$, $p = 0.304$
Survival (months)	$r = 0.106$, $p = 0.933$	$r = -0.119$, $p = 0.350$

Frontal Systems Behavioral Scale (FrSBe). Mini Mental State Examination (MMSE). Edinburgh Cognitive and Behavioral ALS Screen (ECAS). Bold font indicates a statistical significance ($p < 0.05$).

Table 4. Pearson’s correlation of the CSF A β 42/40 ratio with demographic, clinical and neuropsychological features of ALS patients.

Parameters	r^2	p
Age at onset (years)	-0.274	0.008
Diagnostic delay (months)	0.038	0.719
Δ FS	-0.086	0.432
FVC(%)	0.198	0.095
FrSBe	-0.076	0.695
MMSE	0.396	0.019
ECAS	0.054	0.792
Survival (months)	0.164	0.196

Bold font indicates a statistical significance ($p < 0.05$).

To verify if the CSF A β proteins could affect the survival of ALS patients, we stratified ALS patients according to the median values of A β 1–42, A β 1–40 and the A β 42/40 ratio, obtaining three subgroups for each analyzed protein: L-1-Q (i.e., patients with values lower than the first quartile), IQR (i.e., patients with values between the first and the third quartiles) and U-3-Q (i.e., patients with values upper than the third quartile). Only for the A β 42/40 ratio did the Kaplan–Meier analysis with a Holm–Sidak post-hoc test show that L-1-Q patients had a significantly shorter survival (27 (IQR: 17–41) months) in comparison with U-3-Q (39 (IQR: 26–60) months) (log-rank = 6.617; $p = 0.037$) (Figure 2).




Figure 2. Kaplan–Meier survival curves of ALS patients stratified according to the median CSF values of the A β 42/40 ratio: lower than the first quartile (L-1-Q), interquartile range (IQR) and upper than the third quartile (U-3-Q).

Interestingly, patients in the L-1-Q showed a higher median age in comparison with other subgroups (L-1-Q: 71 (66.5–75.25); IQR: 66.5 (63–71.75); U-3-Q: 65.5 (61–70.5); $p = 0.019$).

Subsequently, we performed univariate and multivariate Cox regression analyses to test the predictor role of different demographic and clinical features of ALS patients and the CSF levels of A β 1–42, A β 1–40 and the A β 42/40 ratio. As shown in Table 5, at the univariate regression analysis, the age at onset ($p = 0.001$), diagnostic delay ($p = 0.001$), Δ FS at diagnosis ($p < 0.001$) and A β 42/40 ratio ($p = 0.026$) were significantly associated with overall survival. We then considered variables that were positively related to survival at the univariate analysis for the multivariate Cox regression analysis. As shown in Table 6, the diagnostic delay ($p = 0.025$), Δ FS at diagnosis ($p = 0.032$) and A β 42/40 ratio ($p = 0.015$) were independent predictors of overall survival. Furthermore, the multivariate Cox regression analysis was performed to investigate the role of co-morbidities in overall survival but no significant data were obtained (Table S2).

Table 5. Univariate Cox regression analysis for the overall survival for ALS patients.

Parameters	b	± SE	p	HR	95% CI
Gender (M vs. F)	0.073	0.251	0.772	1.075	0.658–1.757
Age at onset	0.062	0.019	0.001	1.064	1.024–1.105
Site of onset (spinal vs. bulbar)	−0.443	0.271	0.102	0.642	0.378–1.092
Diagnostic delay	−0.038	0.012	0.001	0.963	0.000–0.986
FVC%	0.006	0.006	0.308	0.994	0.982–1.006
ΔFS at diagnosis	0.443	0.105	< 0.001	1.557	1.266–1.914
Aβ 1–42	0.000	0.000	0.862	1	0.999–1.001
Aβ 1–40	0.000	0.000	0.275	1	1–1
Aβ 42/40 ratio	−18.137	8.164	0.026	1.33×10^{-8}	0.000–0.118

b = regression coefficient; SE = standard error; HR = hazard ratio; CI = confidence interval. Bold font indicates a statistical significance ($p < 0.05$).

Table 6. Multivariate Cox regression analysis for overall survival for ALS patients. Significant variables believed to be significant at the univariate analysis were considered for multivariate analysis.

Parameters	b	± SE	p	HR	95% CI
Age at onset	0.038	0.022	0.08	1.038	0.994–1.085
Diagnostic delay	−0.032	0.014	0.025	0.968	0.000–0.996
ΔFS at diagnosis	0.301	0.140	0.032	1.351	1.026–1.779
Aβ 42/40 ratio	−20.662	8.504	0.015	1.6×10^{-9}	0.000–0.018

b = regression coefficient; SE = standard error; HR = hazard ratio; CI = confidence interval. Bold font indicates a statistical significance ($p < 0.05$).

4. Discussion

Our study was aimed at exploring the potential role of Aβ as a prognostic biomarker in ALS. For this purpose, we designed a retrospective observational study that included 93 patients. The CSF Aβ 1–42 and Aβ 1–40 levels and the Aβ 42/40 ratio were determined and correlated with demographic, clinical and neuropsychological features of ALS patients.

In recent years, CSF Aβ levels have been investigated to define their role as potential diagnostic and prognostic biomarkers for ALS and many studies in this field have been reported. However, the two largest studies about this topic found contrasting results. On one hand, higher CSF Aβ 1–42 levels were associated with a poorer prognosis [25] while, on the other hand, an interesting correlation of a higher concentration in patients with better performance was found, reporting increased CSF levels compared with a control group [26].

Even though the CSF Aβ and especially the Aβ 42/40 ratio represent a specific diagnostic biomarker for AD, the idea of shared mechanisms among different neurodegenerative disorders has led many authors to investigate the role of Aβ as a potential modulator of their rate of progression and overall survival. The CSF Aβ 1–42 levels were correlated to conversion from mild cognitive impairment to dementia and the progression of cognitive deficits in AD [27] as well as with the progression of cognitive impairments in Parkinson's disease (PD) [28]. Indeed, lower CSF Aβ 1–42 levels are related to a progressive deposition of Aβ in senile plaques at the cortical level [29]. An intracellular deposition of Aβ 1–42 was also detected in the anterior horn of motor neurons of patients affected by motor neuron disease (MND) [13] while extracellular aggregates of Aβ 1–42 were detected in the hippocampus of ALS and ALS-FTD patients [17]. Studies on murine models of ALS (i.e., SOD1 G93A mice) correlated the overexpression of Aβ with an earlier onset of motor symptoms [30]. Furthermore, few cases of co-morbidity between ALS and AD in a patient showing an overlapping clinical picture have been reported [15,25].

In our study, ALS patients were subdivided into three subgroups (i.e., ALS-s, ALS-i and ALS-r) to analyze the contribution of the CSF Aβ levels on the rate of progression. No statistically significant differences were detected among three subgroups for the CSF Aβ 1–42, Aβ 1–40 and the Aβ 1–42/40 ratio. Indeed, no statistically significant correlation

between the A β and clinical features including the rate of progression was found. We found a significant correlation between the A β 42/40 ratio with the age at onset and MMSE scores.

When analyzing the contribution of the CSF A β 1–42, A β 1–40 and the A β 1–42/40 ratio on overall survival of ALS patients we found that patients with lower A β 42/40 ratio values showed a shorter survival in comparison with those with higher values. This finding was confirmed by univariate and multivariate Cox regression analyses, which showed that the A β 42/40 ratio could act as an independent predictor for overall survival for ALS patients. A decrease in the CSF A β 42/40 ratio values could be indicative of a decrease of the CSF A β 1–42 levels because it might deposit in different districts of the central nervous system (CNS) as previously described [29]. In ALS, the presence of intracellular or extracellular aggregates of A β 1–42 is probably related to an accumulation of APP following neuronal injury. This accumulation could be due to an impairment of axoplasmatic transport or enhanced biosynthesis of APP, representing an early neuroprotective phase to contrast extracellular and intracellular stresses. As the neuronal injuries continue, a shift toward a neurotoxic phase can occur. APP could be subjected to cleavage in A β by alternative mechanisms: caspase 3 giving rise to intracellular aggregates, an accumulation of which gives an increase in oxidative stress, while β -secretase contributes to extracellular deposition [31]. All of these mechanisms may contribute to a decrease of the CSF A β 1–42. Studies on murine models of ALS correlated the production of A β by β -secretase and consequently deposition as a key event that could improve motor functions and survival [32]. For this purpose, those authors treated asymptomatic and symptomatic SOD-1 G93A mice with a monoclonal antibody able to interfere with β -secretase activity, avoiding the formation of intracellular or extracellular A β aggregates: treated asymptomatic ALS mice showed a delay of the onset of symptoms, motor failure and death; however, the same effects were not obtained in treated symptomatic ALS mice.

Another interesting result that we obtained was related to the evidence that ALS patients with lower A β 42/40 ratio values presented a higher age at onset than those with higher values. These data were enforced with the finding that there was a statistically significant correlation of A β 42/40 ratio values with the age at onset. Considering that the age at onset was considered a strong prognostic factor for ALS [33] and that in cognitively normal subjects the concentration of the CSF AD biomarkers, including the A β 42/40 ratio, is associated with age [34], the decrease of the A β 42/40 ratio in the CSF of ALS patients might indicate that the triggering of the A β cascade could represent an early event that leads to an asymptomatic form of dementia that fails to fully become symptomatic as death occurs. Thus, the coexistence of an elevated age at onset and a low CSF A β 42/40 could represent a more severe prognostic condition that could influence survival time. The evidence that ALS patients with a low CSF A β 42/40 ratio had a high median age at onset make us speculate that the intracellular or extracellular deposition of A β would accelerate the course of the disease, worsening their survival. Indeed, we cannot exclude that a few patients in our population could have a preclinical condition of AD or the presence of age-related amyloid deposition.

Our study had a few limitations. First, the sample size. We studied 96 patients but, for our analyses, we stratified these into three groups resulting in quite small numbers. Related to that is the difference of the age of onset among groups that could partially reduce the significance of our results. Another limitation was the lack of a follow-up for the cognitive formal evaluation. This could have been useful for a correlation with the clinical progression but we found no correlation at the baseline and none of our patients developed clinically significant dementia. Finally, the lack of a control population represented a further limitation. Our goal was to assess the role of the CSF A β 1–42, A β 1–40 and the A β 42/40 ratio in the clinical progression of patients affected by ALS and a comparison with a control group could have enriched our work but we did not consider this to be mandatory.

5. Conclusion

In our study, we aimed to evaluate the potential role of A β in predicting the prognosis in ALS patients. We found that A β 42/40 is an independent predictor for survival and could be proposed as a potential prognostic biomarker as suggested by previous reports. Further studies are needed to confirm our findings in a larger population but we consider that we have added a piece to the understanding and management of the disease.

Supplementary Materials: The following are available online at <https://www.mdpi.com/2076-3425/11/3/302/s1>, Table S1: Neuropsychologic assessment of ALS patients by FrSBe, MMSE and ECAS at the time of diagnosis (baseline). Table S2: Multivariate Cox regression analysis for overall survival for ALS patients considering their co-morbidities.

Author Contributions: T.C. collected samples, performed statistical analyses, reviewed the data and drafted the manuscript; L.A. made the assays, reviewed the data and the manuscript; R.S. performed clinical evaluations, reviewed the data and the manuscript; L.G. performed neuropsychologic evaluations, reviewed the data and the manuscript; A.N. collected samples, reviewed the data; V.B. performed neuropsychologic evaluations, reviewed the data and the manuscript; F.G. performed clinical evaluations, reviewed the data and the manuscript; B.L.S. made the assays, reviewed the data and the manuscript; C.M.G. made the assays, reviewed the data and the manuscript; R.V.G. made the assays, reviewed the data and the manuscript; G.B. made the assays, reviewed the data and the manuscript; V.L.B. designed the study, performed clinical evaluations and reviewed the data and the manuscript; M.C. designed the study, wrote the original draft, reviewed the data and the manuscript; T.P. designed the study, performed statistical analyses, wrote the original draft, reviewed the data and the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of University Hospital “Paolo Giaccone” (Institutional Ethic Committee Palermo 1 n° 07/2017).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study. The informed consent contained a statement that the biological material may also be used for research purposes.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to current privacy laws.

Acknowledgments: This study performed at University Hospital of Palermo is the result of trans-disciplinary collaboration of ALS Research and Clinical Center of Palermo, Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory Medicine and IRCSS Bonino Pulejo. The Authors feel grateful for such and lively collaboration.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Van Es, M.A.; Hardiman, O. Amyotrophic lateral sclerosis. *Lancet* **2017**, *390*, 2084–2098. [[CrossRef](#)]
2. Brooks, B.R.; Miller, R.G. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph. Lateral. Scler. Other Motor. Neuron. Disord.* **2000**, *1*, 293–299. [[CrossRef](#)] [[PubMed](#)]
3. Julien, J.P. A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis. *Biochem. Cell Biol.* **1995**, *73*, 593–597. [[CrossRef](#)]
4. Didonna, A.; Opal, P. The role of neurofilament aggregation in neurodegeneration: Lessons from rare inherited neurological disorders. *Mol. Neurodegener.* **2019**, *14*, 19. [[CrossRef](#)]
5. Steinacker, P.; Feneberg, E. Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients. *J. Neurol. Neurosurg. Psychiatry* **2016**, *87*, 12–20. [[CrossRef](#)]
6. Rossi, D.; Volanti, P. CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. *J. Neurol.* **2018**, *265*, 510–521. [[CrossRef](#)]
7. Paladino, P.; Valentino, F. Cerebrospinal fluid tau protein is not a biological marker in amyotrophic lateral sclerosis. *Eur. J. Neur.* **2009**, *16*, 257–261. [[CrossRef](#)]
8. Grossman, M.; Elman, L.; McCluskey, L. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. *JAMA Neurol.* **2014**, *71*, 442–448. [[CrossRef](#)] [[PubMed](#)]

9. Wilke, C.; Deuschle, C. Total tau is increased, but phosphorylated tau not decreased, in cerebrospinal fluid in amyotrophic lateral sclerosis. *Neurobiol. Aging* **2015**, *36*, 1072–1074. [[CrossRef](#)] [[PubMed](#)]
10. Burrell, J.R.; Halliday, G.M. The frontotemporal dementia-motor neuron disease continuum. *Lancet* **2016**, *388*, 919–931. [[CrossRef](#)]
11. DeJesus-Hernandez, M.; Mackenzie, I.R. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. *Neuron* **2011**, *72*, 245–256. [[CrossRef](#)]
12. Renton, A.E.; Majounie, E. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* **2011**, *72*, 257–268. [[CrossRef](#)] [[PubMed](#)]
13. Calingasan, N.Y.; Chen, J. B-Amyloid 42 Accumulation in the Lumbar Spinal Cord Motor Neurons of Amyotrophic Lateral Sclerosis Patients. *Neurobiol. Dis.* **2005**, *19*, 340–347. [[CrossRef](#)]
14. Farid, K.; Carter, S.F.; Rodriguez-Vieitez, E. Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition. *JAD* **2015**, *47*, 661–667. [[CrossRef](#)] [[PubMed](#)]
15. Sasaki, S.; Iwata, M. Immunoreactivity of beta-amyloid precursor protein in amyotrophic lateral sclerosis. *Acta Neuropathol.* **1999**, *97*, 463–468. [[CrossRef](#)]
16. Gómez-Pinedo, U.; Villar-Quiles, R.N. Immununochemical Markers of the Amyloid Cascade in the Hippocampus in Motor Neuron Diseases. *Front Neurol.* **2016**, *7*, 195. [[CrossRef](#)]
17. Hardy, J. Alzheimer's disease: The amyloid cascade hypothesis—An update and reappraisal. *JAD* **2009**, *9*, 151–153. [[CrossRef](#)]
18. Jack, C.R.; Bennett, D.A. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* **2018**, *14*, 535–562. [[CrossRef](#)]
19. Albert, M.S.; DeKosky, S.T. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* **2011**, *7*, 270–279. [[CrossRef](#)]
20. McKhann, G.M.; Knopman, D.S. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* **2011**, *7*, 263–269. [[CrossRef](#)] [[PubMed](#)]
21. Eun, J.Y.; Hyo-Jin, P. Intracellular amyloid beta interacts with SOD1 and impairs the enzymatic activity of SOD1: Implications for the pathogenesis of amyotrophic lateral sclerosis. *Exp. Mol. Med.* **2009**, *41*, 611–617.
22. Stanga, S.; Brambilla, L. A role for GDNF and soluble APP as biomarkers of amyotrophic lateral sclerosis pathophysiology. *Front. Neurol.* **2018**, *9*, 1–9. [[CrossRef](#)]
23. Steinacker, P.; Hendrich, C. Concentrations of beta-amyloid precursor protein processing products in cerebrospinal fluid of patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. *J. Neural. Transm.* **2009**, *116*, 1169–1178. [[CrossRef](#)] [[PubMed](#)]
24. Rusina, R.; Ridzon, P. Relationship between ALS and the degree of cognitive impairment, markers of neurodegeneration and predictors for poor outcome. A prospective study. *Eur. J. Neurol.* **2010**, *17*, 23–30. [[CrossRef](#)]
25. Lanznaster, D.; Hergesheimer, R.C. A β 1-42 and Tau as Potential Biomarkers for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis. *Int. J. Mol. Sci.* **2020**, *21*, 2911. [[CrossRef](#)]
26. Hadjichrysanthou, C.; Evans, S. The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. *Alzheimers Res. Ther.* **2020**, *12*, 74. [[CrossRef](#)]
27. Hall, S.; Surova, Y. CSF biomarkers and clinical progression of Parkinson disease. *Neurology* **2015**, *84*, 57–63. [[CrossRef](#)]
28. Hansson, O.; Seibyl, J. CSF biomarkers of Alzheimer's disease concord with amyloid- β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimers Dement* **2017**, *14*, 1470–1481. [[CrossRef](#)]
29. Li, Q.X.; Mok, S.S. Overexpression of A β is associated with acceleration of onset of motor impairment and superoxide dismutase 1 aggregation in an amyotrophic lateral sclerosis mouse model. *Aging Cell.* **2006**, *5*, 153–165. [[CrossRef](#)] [[PubMed](#)]
30. Sjögren, M.; Davidsson, P. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. *Dement. Geriatr. Cogn. Disord.* **2002**, *13*, 112–118. [[CrossRef](#)] [[PubMed](#)]
31. Rabinovich-Toidman, P.; Becker, M. Inhibition of amyloid precursor protein beta-secretase cleavage site affects survival and motor functions of amyotrophic lateral sclerosis transgenic mice. *Neurodegener. Dis.* **2012**, *10*, 30–33. [[CrossRef](#)] [[PubMed](#)]
32. Chiò, A.; Logroscino, G. Prognostic factors in ALS: A critical review. *Amyotroph. Lateral. Scler.* **2009**, *10*, 310–323. [[CrossRef](#)] [[PubMed](#)]
33. Paternicò, D.; Galluzzi, S. Cerebrospinal fluid markers for Alzheimer's disease in a cognitively healthy cohort of young and old adults. *Alzheimer's Dement.* **2012**, *8*, 520–527. [[CrossRef](#)] [[PubMed](#)]
34. Rodrigue, K.M.; Kennedy, K.M. Beta-amyloid deposition and the aging brain. *Neuropsychol. Rev.* **2009**, *19*, 436–450. [[CrossRef](#)] [[PubMed](#)]